Who to call at Citius Oncology, Inc., and when
Fundz watches for the moments Citius Oncology, Inc. starts buying, and tells you who to reach.
- An alert the day Citius Oncology, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Citius Oncology, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Citius Oncology, Inc.. With Fundz connected, it knows.
Citius Oncology, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
citiuspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
At its October 27, 2025 annual meeting, Citius Oncology stockholders approved doubling the share reserve under the 2024 Omnibus Stock Incentive Plan from 15,000,000 to 30,000,000 shares, elected Myron Holubiak and Joel Mayersohn as Class I directors, and ratified Wolf & Company, P.C. as auditor. The routine votes passed with strong support, but the larger equity pool expands potential dilution.
Key Takeaways
Stockholders approved raising the 2024 Omnibus Stock Incentive Plan share authorization from 15,000,000 to 30,000,000 shares, with 74,220,840 votes for against 106,247 against.
Myron Holubiak and Joel Mayersohn were elected as Class I directors for three-year terms expiring at the 2028 annual meeting, with each receiving roughly 74.3 million votes for.
3 more takeaways
Related Filings (14)
14 more filings from Citius Oncology, Inc. in the last 90 days
Filing Overview
What This Means
Citius Oncology, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.